Objective: To examine serologic markers of vascular risk under treatment with commonly used antiepileptic drugs (AEDs) in the elderly in a randomized setting, and to determine whether the reduced exposure to hydroxymethylglutaryl-CoA reductase inhibitors ("statins") caused by carbamazepine reduces the effectiveness of the drugs as lipid-lowering agents. Methods: Standard lipid fractions, lipoprotein(a), and C-reactive protein (CRP) were examined in a subset of those participating in the STEP-ONE trial, in which elderly patients with new epilepsy were randomized to treatment with carbamazepine, lamotrigine, or levetiracetam. Separate comparisons were made by individual AED, among those treated with statins, and, for CRP, among those treated with anti-inflammatory drugs. Results: One hundred ninety-four patients had the aforementioned serologic measurements. In patients not taking statins, those treated with carbamazepine had higher total cholesterol than those treated with levetiracetam (+16.6 mg/dL, P = 0.053), with values from patients on lamotrigine intermediate, whereas cholesterol fractions were subject to drug-gender interactions which did not show a consistent pattern.
| INTRODUCTION
Considerable evidence has suggested that enzyme-inducing antiepileptic drugs (AEDs) significantly elevate serum lipids and C-reactive protein (CRP). This evidence has come from both cross-sectional studies and longitudinal repeated-measures analyses. 1 The former have shown that patients taking carbamazepine (CBZ), phenytoin (PHT), or phenobarbital have higher lipid levels and higher CRP than those who take other agents. 2, 3 The latter have shown elevations in serum lipids after initiation of CBZ 4 and, furthermore, that patients switching from CBZ or PHT to other drugs with less or no effect on the cytochrome P450 (CYP) system experience a significant decline in these markers. [5] [6] [7] [8] These data all derive from repeated-measures studies, in which patients serve as their own controls. To date, to our knowledge, there have been no randomized studies of AED-lipid effects in any population.
Another gap in our current knowledge pertains to the elderly. This is, of course, the group of patients most at risk from potential AED-induced hyperlipidemia, given their high rates of cardiovascular and cerebrovascular disease. Despite this, we are unaware of any investigations of AED-induced lipid effects among elderly patients.
A recently completed treatment trial for elderly patients with new-onset epilepsy in Germany, Austria, and Switzerland offered an opportunity to overcome both of these limitations. Subjects were randomized to CBZ, lamotrigine (LTG), and levetiracetam (LEV), and the primary efficacy and safety results have already been reported. 9 A subset of subjects in this trial had lipid and CRP levels obtained over its course, allowing us for the first time to determine the impact of these 3 drugs on serum lipids in the elderly. In addition, this study represents the first-ever randomized investigation into AED-induced lipid effects. The size of the trial also allowed us to investigate one other crucial issue that has never before been addressed: the functional impact of the interaction between CBZ and hydroxymethylglutaryl-CoA reductase inhibitors ("statins"). There is clear pharmacokinetic evidence of interaction between CBZ and several of the statin drugs; the latter are (with one exception) metabolized by the CYP system, which is strongly induced by CBZ. Thus, one would expect reduced statin exposure among CBZ-treated patients, and this is, in fact, seen clinically. 10 Reduced statin exposure should, in turn, lead to elevated lipids. However, teasing out the impact of this functional consequence is not a simple matter, since CBZ has its own inherent lipid-elevating properties.
The data from STEP-ONE included a large number of patients who were treated with a statin agent. Because of this, we had the opportunity to measure the impact of CBZ on both statin-treated and non-statin-treated patients, and thus obtain some measure of the impact of the drug interaction on lipid levels, as distinct from the impact of CBZ alone.
| METHODS
This was a post hoc analysis of serologic data obtained from a randomized, double-blind, active comparator, multicenter, parallel-group trial conducted over 58 weeks in Germany, Austria, and Switzerland to look at the efficacy and tolerability of 3 different AEDs for treatment of new-onset epilepsy in the elderly. 9 It comprised a 6-week titration followed by a 52-week maintenance period. Patients were randomized 1:1:1 to controlled-released CBZ, LTG, or LEV. In this trial, 362 patients were included if they were older than 60 years and either had 2 spontaneous epileptic seizures with one occurring in the last 6 months, or one seizure plus epileptiform activity on electroencephalography (EEG), or an enduring relevant lesion on imaging. Patients were not to be treated before with AEDs, except for transient emergency treatment after the first seizure. Major exclusion criteria were seizures as the consequence of acute brain damage, dementia, renal failure, and drug abuse. After randomization, study medication was titrated over 6 weeks to initial target doses of 400 mg/d CBZ, 100 mg/d LTG, or 1000 mg/d LEV, divided into 2 equal doses/d. After reaching target doses, dose adjustments were allowed according to tolerability and seizure control in steps of one capsule per week to doses between 200 and 1200 mg for CBZ, 50 and 300 mg for LTG, and 500 and 3000 mg for LEV to mimic clinical practice. Patients who did not tolerate a study drug within this dose range or whose seizures
Key Points
• Total cholesterol was higher in carbamazepinetreated elderly patients than in those taking levetiracetam • Other lipid markers yielded drug-gender interactions without a consistent pattern, in contrast to prior work • C-reactive protein was higher in carbamazepinetreated elderly patients than in those taking levetiracetam or lamotrigine • "Statins" had markedly less effect on serum cholesterol in patients taking carbamazepine than in those taking lamotrigine or levetiracetam • These results suggest that carbamazepine may be a poor choice for patients who are at risk for vascular disease recurred despite the maximum dose had to be withdrawn. Full details regarding study visits are available in the original trial report. 9 For the purpose of this study, serum measurements at V0 (baseline before treatment), V2 (6 weeks after randomization) and V6 (58 weeks after randomization) were assessed and compared retrospectively. The primary endpoint was serum levels at V2 and V6 compared to baseline in the CBZ arm. Secondary end points included a comparison of serum parameters between patients treated with LEV, LTG, or CBZ and the incidence of vascular adverse events (AEs), or comorbid conditions in the CBZ arm and compared to the other 2 treatment arms.
Lab values of the n = 361 patients included (CBZ n = 121, LTG n = 118, LEV n = 122) in the STEP-ONE study were reviewed locally by the treating physician before randomization and at V2 and V6 to ensure eligibility and for safety assessments as part of the main protocol. In parallel, for serum collection, at visit V2 (week 6 after randomization) and V6 (week 52), blood samples were collected (serum S-Monovette; Sarstedt, Nümbrecht, Germany) along with serum chemistry/hematology samples. All samples were preprocessed immediately after blood was drawn in tubes containing a separator gel. Each blood sample was centrifuged 10 minutes at 4000 U/min. One milliliter supernatant (serum) was transferred into a 1.5 mL polypropylene tube (Eppendorf tube) and stored below −20°C at each study center. Overnight shipment to the central laboratory was then done with study close-out. The central laboratory stored serum samples below −20°C until analysis. After study closure, approximately half of the samples were missing or could not be evaluated at the central lab (CBZ n = 55 [46%], LTG n = 59 [50%], and LEV n = 62 [51%]) for various logistical or technical reasons (delivery failure, not collected at site, not stored correctly, missing probes at central lab some years after study closure, unidentifiable probe, low serum quantity, or denatured probe) with a similar frequency among treatment arms. The samples were measured en bloc after collection. Values of a given subject were included only in the present analysis with a complete dataset from all 3 visits (V0, V2, V6) and samples of subjects with missing samples at any visit were discarded. The central laboratory, The Institute of Clinical Chemistry and Laboratory Medicine, University of Mainz, Germany is accredited according to DIN EN ISO/IEC 17025 and certified according to DIN EN ISO 9001:1994. This trial was conducted in accordance with the Declaration of Helsinki, with good clinical practice guidelines and with Austrian, German, and Swiss law, as applicable. National and local independent ethics committees, where appropriate, approved the protocol. Written informed consent was obtained from all patients before admission into the trial.
| Statistical analysis
Total cholesterol (TC), LDL cholesterol (LDL-C), HDL cholesterol (HDL-C), non-HDL cholesterol (non-HDL-C = Total − HDL-C), triglycerides (TRIG), lipoprotein(a) (LP (a)) and C-reactive protein (CRP) measures were analyzed using separate linear mixed-effects (LME) models with random patient effect to allow for correlation between visit 2 and visit 6 measures from the same patient. The TRIG, LP (a), and CRP measures were log-transformed to satisfy the assumptions of the LME model. The candidate fixed-effects predictors included epilepsy drug (CBZ, LTG, or LEV), age, sex, body-mass index (BMI), visit (V02 or V06), the use of any lipid-lowering agent, the use of aspirin or aspirin-containing preparations (ASA), the use of non-steroidal antiinflammatory drugs (NSAID), and the use of steroids. In addition, the interaction between the epilepsy drug and sex was considered in all models, and interaction between the epilepsy drug and the use of any lipid-lowering agent was considered in the models for lipids measures. The initial models were reduced to parsimonious models using backward elimination of nonsignificant predictors, except that the interaction between the epilepsy drug and use of any lipidlowering agent was kept in the models for standard lipid measures (TC, HDL-C, LDL-C, and non-HDL-C).
| RESULTS
Demographic information for the subjects is shown in Table 1 . The overall sample included a higher proportion of males, as is commonly the case in randomized trials. 11 More unusual is the fact that there was an imbalance in AED distribution by gender in this subgroup of the trial, with a significantly larger fraction of women getting CBZ (44%) and a significantly smaller fraction receiving LEV (27%). As AED assignments were done in a random and equal fashion, this means that fewer of the women assigned to LEV and more of the women assigned to CBZ had lipid levels measured; this did not appear to be true of the men. Statistical analyses reported are adjusted for this imbalance when necessary by including gender by AED interaction when it is significant.
| Lipid fractions
Overall results for various lipid fractions are seen in Tables 2-5 . For TC in the whole study cohort, there were differences based upon co-medications, with NSAID-treated patients having lower TC (−12.2 mg/dL, P = 0.033), and ASA-treated patients having higher TC (10.9 mg/dL, P = 0.046). These comedications were therefore included as covariates for TC.
Among patients not taking lipid-lowering agents, CBZtreated patients had TC levels 16.6 mg/dL higher than those treated with LEV, which was marginally significant (P = 0.053), whereas LTG-treated patients had levels in between these 2 (P > 0.1 for comparisons to both other drugs) ( Table 2 ). Differences in HDL-C among patients not taking lipid-lowering agents were small and nonsignificant, as were the differences in LDL-C.
For both LDL-C and non-HDL-C (defined as TC minus HDL-C), the total population (including those taking and not taking hyperlipidemic agents) yielded a significant drug-by-gender interaction (Tables 4 and 5 ). Men treated with CBZ had higher LDL-C and non-HDL-C than male patients treated with LTG or LEV (P < 0.05 for CBZ vs LTG, and P < 0.01 for CBZ vs LEV for each measure); there was no difference between the LTG-and LEV-treated men. In contrast, among women, LDL-C and non-HDL-C were highest in the LEV-treated group and lowest in the LTG-treated group (P = 0.023 and P = 0.004 respectively), with the CBZ group falling in-between (not different from either group in LDL-C, but lower than the LEV group in non-HDL-C, P = 0.046).
TRIG were not impacted by drug overall, or by the use of lipid-lowering agents. However, a significant drug-bygender interaction was once again present in the whole cohort (Figure 1 ). Among men, TRIG were significantly higher in those taking CBZ (P~0.01 vs both LTG and LEV); in women, those taking CBZ had significantly lower TRIG than women taking LTG (P = 0.044), with LEVtreated women having intermediate values (not different from either of the other groups).
| Impact on lipid-lowering agents
The impact of the 3 AEDs on cholesterol fractions in patients taking lipid-lowering agents is shown in Figure 2 . For TC, non-HDL-C, and LDL-C, those on lipid-lowering agents had lower lipid levels than those who did not, regardless of which AED they were taking, as would be expected. Among LEVand LTG-treated patients, the differences between those taking lipid-lowering agents and those who did not were very large; among the CBZ-treated patients, the difference was smaller. Statistical analysis demonstrated a significant interaction effect between AED and use of lipid-lowering agent for TC (P = 0.035) and a statistical trend toward a difference with respect to LDL-C (P = 0.094).
| Other vascular risk markers
Lp(a) was higher in both the CBZ group and the LEV group than in the LTG group (P < 0.05 for each) ( Table 6 ). For CRP, steroid treatment was associated with reduced CRP levels, as would be expected, but NSAID treatment was not. After accounting for this, CBZ-treated patients had higher CRP levels than LTG-treated patients (P = 0.006), with the LEV group being intermediate, and not significantly different from the other 2. Differences between the drugs in CRP were essentially effaced in the presence of steroid treatment, but elevation of CRP in the CBZ-treated patients is apparent in those not taking steroids ( Figure 3 ).
T A B L E 3 Differences in HDL cholesterol

| DISCUSSION
This study is novel in a number of important respects. It is the first study to examine lipids and other vascular risk markers in a randomized population. It is the first study to examine these markers in the elderly, which typically make up only a small portion of the cohort in AED studies. Finally, it is the first study to examine the functional impact of AED use on lipid-lowering agents using the most relevant measure-serum lipid levels-rather than drug exposure. The findings with regard to the latter of these are the most striking. Atherogenic lipid levels were lower in all 3 drug-treated groups when there was cotreatment with a lipid-lowering agent, which is, of course, to be expected. But the differences in TC were very large in the LEV-and LTG-treated groups-on the order of 40 mg/dL-whereas in the CBZ group the difference was less than half that.
There are 2 potential causes for these differences. CBZ could be reducing the effectiveness of the "statin" agents, possibly by inducing their metabolism, as most of them are CYP substrates; in fact, a few pharmacokinetic studies have shown that this is likely. 10, 12 Alternatively, this could be due to the native lipid-elevating properties of CBZ itself, which have been demonstrated in a number of investigations. 4, [6] [7] [8] 13 To tease this out, we can examine differences in TC levels among the drug-treated groups in patients not taking a lipid-lowering agent, to isolate the effect of the AED; those differences were only 6-17 mg/dL. These are lower than those seen in other studies, but even in those latter studies, differences were more on the order of 20-25 mg/dL. Because CBZ alone causes an effect size in this range, whereas CBZ along with lipid-lowering agents produces an effect size of 30-40 mg/dL, this suggests that CBZ blunts the ability of lipid-lowering agents to lower lipids, by perhaps 30%-50%. This makes the use of CBZ a "double whammy" with respect to lipid levels. First, it will increase serum lipids itself; second, it will make treatment of this hyperlipidemia more difficult. In theory, a nonmetabolized statin such as rosuvastatin might be an alternative; in practice, however, there is evidence that rosuvastatin too may be impacted by treatment with AEDs in the dibenzazepine family, for reasons not entirely clear. 14 In any case, it is poor medical practice to use a drug that will require treatment with another drug to mitigate side effects, unless there is no good recourse. Furthermore, interference with these lipidlowering effects may have profound clinical consequences, given that the relative risk of myocardial infarction increases about 1% for every 1 mg/dL increase in atherogenic lipids. 15, 16 Thus, it is also worth posing the question of whether CBZ should be used in the first place, given [17] [18] [19] This is especially true in patients who will need statin treatment, either for hyperlipidemia or for cardiovascular disease prevention.
Although the results with respect to drug interaction were consistent and concordant with other lines of evidence, this was not the case with regard to the impact on lipids in patients not taking lipid-lowering agents. TC was marginally higher in CBZ patients than in LEV patients, but there was no difference between the LTG and CBZ groups, in contrast to prior studies. 6, 8, 20 Data on lipid fractions also showed some gender-based discrepancies. Among men, atherogenic lipid fractions were elevated in the CBZ group relative to the other AED groups, consistent with prior studies, but in women, atherogenic lipid levels were actually highest among LEV-treated patients, which has not been seen before. 6, 8 With regard to the other vascular risk markers analyzed, our data on Lp(a) are consistent with previous findings, and CRP was elevated with CBZ treated relative to LTG treatment, which also confirms prior work; however, LEV-treated patients had intermediate CRP values, which contradicts previous investigations. 6, 8 The reasons for the latter discrepancies are not obvious. We did not correct for multiple comparisons, as the procedures to do so are conservative. 21, 22 Furthermore, the Tables 2-5 ), implying relatively low power for detecting clinically meaningful differences even without such correction. Notwithstanding this, it is possible that the finding of elevated LDL-C and non-HDL-C among LEVtreated women is a statistical fluke that will not be reaffirmed in the future. Even if this were the case, this explanation does not suffice for the negative findings that contradict prior work, however. Theoretically, it is possible that elderly patients-perhaps elderly women in particular-respond differently than nonelderly patients to these AEDs. It is not clear why this might be the case, however. Another possibility is that this is a genetic variation; Germany and Austria, which provided the large majority of patients for this study, are rather ethnically homogeneous countries, and it is possible that these patients may have genes that cause them to respond to these AEDs in ways that are somewhat different from others. There is a precedent for this, as a series of studies in a Finnish population show lipid responses to phenytoin that are quite different from those seen in other populations. 1 Another possibility is that there was some undetected bias in our sample. The study was randomized, which should have prevented this; unfortunately, because this was not the primary focus of the trial, only a subset of patients could have vascular risk markers measured, and perhaps this introduced a bias based on geography, logistics, or other factors. Again, this is speculative, and it is uncertain exactly how this, or any of the preceding factors, might have produced the findings. Lipid measurements were obtained in the nonfasting state; there is emerging evidence and consensus that nonfasting lipids are as predictive of cardiac risk as fasting levels, 23 so we doubt this had any impact except for TRIG levels, which may not be reliable when performed without fasting. Further studies are needed to elucidate the effects of AEDs on lipids in more detail. Because CBZ is commonly used as a "standard" treatment arm in European trials, future randomized studies of AEDs might plan specifically for measurement of lipids before and after treatment to clarify the ambiguities present in our results. At minimum, these data add to the concern that CYP-inducing AEDs such as CBZ may adversely affect vascular risk markers. In addition, our data provide strong evidence that CBZ undermines the primary action of lipid-lowering agents, making it a poor choice for those at risk for vascular disease who require treatment with these agents.
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